On the 22nd of March, Point72 Asset Management purchased 5.3 million Curis Inc (CRIS) shares for $68 million at an average price of $12.77 per share. Shares of Curis Inc are down -7.20% since the transaction.
Point72 Asset Management's holding in Curis Inc established a new holding of about 5.3 million shares with the purchase.
Point72 Asset Management first bought Curis Inc stock in the fourth quarter of 2020. Point72 Asset Management also owns Alnylam Pharmaceuticals Inc (ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Biogen Inc (NASDAQ:BIIB) and Dicerna Pharmaceuticals, Inc. (DRNA). Curis Inc is its number one position by number of shares and market value among pharmaceuticals stocks.
Other investors who also established new holdings in Curis Inc include Farallon Capital Management, the T. Rowe Price Equity Income Fund, and Victory Capital Management. Contrary to Point72 Asset Management, Millennium Management and Squarepoint Ops reduced CRIS shares.
Point72 Asset Management has also recently reduced their share in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), Cytokinetics Inc (NASDAQ:CYTK), Otonomy, Inc. (NASDAQ:OTIC), Calithera Biosciences, Inc. (CALA), Chiasma Inc (NASDAQ:CHMA) and Fulcrum Therapeutics, Inc. (NASDAQ:FULC). The total value of the shares sold is estimated at around $29 million.
In addition, Point72 Asset Management established new holdings in Aeglea BioTherapeutics, Inc. (AGLE). Point72 Asset Management also increased their share in BioCryst (NASDAQ:BCRX) Pharmaceuticals Inc (BCRX) and Acorda Therapeutics Inc (NASDAQ:ACOR). The total value of the shares bought is estimated at around $45 million.
Point72 Asset Management also reduced their share in VYNE Therapeutics INC (VYNE), American Eagle Outfitters Inc (NYSE:AEO), Childrens Place Inc (PLCE), ANGI Homeservices Inc (NASDAQ:ANGI), Dave & Busters Entertainment Inc (NASDAQ:PLAY) and MacroGenics, Inc. (NASDAQ:MGNX). The total value of the shares sold is estimated at around $85 million.
In addition, Point72 Asset Management established new holdings in Miragen Therapeutics Inc (NASDAQ:VRDN), CytomX Therapeutics, Inc. (NASDAQ:CTMX), AnaptysBio, Inc. (NASDAQ:ANAB), Hims & Hers Health, Inc. (HIMS) and Paya Holdings Inc. (PAYA). Point72 Asset Management also increased their share in Alliance Data Systems Corp (NYSE:ADS), BGC Partners Inc (NASDAQ:BGCP), Affimed N.V. (NASDAQ:AFMD), Kadmon Holdings Inc (NASDAQ:KDMN), Bicycle Therapeutics plc (NASDAQ:BCYC), Revolve Group Inc (NYSE:RVLV), Tricida , Inc. (NASDAQ:TCDA) and Mereo BioPharma Group plc (MREO). The total value of the shares bought is estimated at around $304 million.